{
  "paper_id": "PMC9813109",
  "url": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9813109/",
  "figures": {
    "figure_1": {
      "figure_number": "Figure 1",
      "title": "Fig. 1.",
      "caption": "Patient disposition MTD Maximum tolerated dose, PDy pharmacodynamics, PK pharmacokinetics",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/6ba1af6b6f69/12185_2022_3464_Fig1_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/6ba1af6b6f69/12185_2022_3464_Fig1_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/6ba1af6b6f69/12185_2022_3464_Fig1_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/6ba1af6b6f69/12185_2022_3464_Fig1_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig1",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/6ba1af6b6f69/12185_2022_3464_Fig1_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9813109/images/figure_1.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/6ba1af6b6f69/12185_2022_3464_Fig1_HTML.jpg"
    },
    "figure_2": {
      "figure_number": "Figure 2",
      "title": "Fig. 2.",
      "caption": "Mean plasma concentration–time curves of milademetan A Day 1 of cycle 1; B day 14 of cycle 1. Cohort 1, 90 mg 14/28 once daily; cohort 2, 120 mg 14/28 once daily; and cohort 3, 160 mg 14/28 once daily. Data represent the arithmetic mean ± standard deviation",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/96f04d1dffc1/12185_2022_3464_Fig2_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/96f04d1dffc1/12185_2022_3464_Fig2_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/96f04d1dffc1/12185_2022_3464_Fig2_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/96f04d1dffc1/12185_2022_3464_Fig2_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig2",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/96f04d1dffc1/12185_2022_3464_Fig2_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9813109/images/figure_2.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/96f04d1dffc1/12185_2022_3464_Fig2_HTML.jpg"
    },
    "figure_3": {
      "figure_number": "Figure 3",
      "title": "Fig. 3.",
      "caption": "Mean macrophage inhibitory cytokine-1 (MIC-1) serum level C cycle, D day, MIC-1 macrophage inhibitory cytokine-1",
      "possible_urls": [
        [
          "original_src",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/ae0c07d8c251/12185_2022_3464_Fig3_HTML.jpg"
        ],
        [
          "large_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/ae0c07d8c251/12185_2022_3464_Fig3_HTML.jpg?maxwidth=2000"
        ],
        [
          "original_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/ae0c07d8c251/12185_2022_3464_Fig3_HTML.jpg?size=original"
        ],
        [
          "xlarge_size",
          "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/ae0c07d8c251/12185_2022_3464_Fig3_HTML.jpg?maxwidth=4000"
        ]
      ],
      "figure_id": "Fig3",
      "is_table": false,
      "working_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/ae0c07d8c251/12185_2022_3464_Fig3_HTML.jpg",
      "download_success": true,
      "local_image_path": "./data/PMC9813109/images/figure_3.jpg",
      "final_url": "https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fda6/9813109/ae0c07d8c251/12185_2022_3464_Fig3_HTML.jpg"
    }
  },
  "claims": [
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Four fixed-dose milademetan schedules were planned (Supplementary Fig. 1A).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel A",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Increases in the milademetan dose were guided by the modified continual reassessment method (mCRM), with a planned maximum dose of 160 mg/day (Supplementary Fig. 1B).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "Panel B",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Summary of neutrophil and platelet counts across all visits were presented in supplementary Table 2.Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Patients’ disposition and baseline characteristics\nFollowing written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Following written informed consent, 14 patients were enrolled in this study, of which four, six, and four were placed in the 90-, 120-, and 160 mg treatment cohorts, respectively (Fig. 1).",
      "figure_references": [
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        },
        {
          "figure_number": "Figure 1",
          "panel": "",
          "figure_key": "figure_1"
        }
      ]
    },
    {
      "sentence": "Pharmacokinetics\nThe plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The plasma concentration–time profile of milademetan for days 1 and 14 of cycle 1 in the QD 14/28-day schedule is shown in Fig. 2.",
      "figure_references": [
        {
          "figure_number": "Figure 2",
          "panel": "",
          "figure_key": "figure_2"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The best percent change of blast count from baseline to the end of treatment by TP53 status at the baseline in each patient’s bone marrow is shown as a waterfall plot (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "The serum MIC-1 level, in most patients, reached a peak on day 8 or 14 of cycle 1 and then decreased to near baseline levels on day 22 of cycle 1 or later (Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        },
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction in baseline blast count in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    },
    {
      "sentence": "Four (33.3%) patients had a ≥ 50% reduction of blast count from baseline in the bone marrow aspirate (Supplementary Fig. 3).",
      "figure_references": [
        {
          "figure_number": "Figure 3",
          "panel": "",
          "figure_key": "figure_3"
        }
      ]
    }
  ],
  "extraction_stats": {
    "figures_count": 3,
    "claims_count": 89,
    "images_downloaded": 3,
    "tables_filtered": 431
  }
}